- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 861924, 7 pages
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
1Cardiology Consultants of Philadelphia, Philadelphia, PA 19107, USA
2Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA 19107, USA
3Department of Epidemiology and Biostatistics, Drexel University School of Public Health, Philadelphia, PA 19107, USA
Received 17 April 2012; Revised 10 June 2012; Accepted 12 June 2012
Academic Editor: Jan Wouter Jukema
Copyright © 2012 Dean G. Karalis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- V. L. Roger, A. S. Go, D. M. Lloyd-Jones, et al., “Heart disease and stroke statistics—2011 update: a report from the American Heart Association,” Circulation, vol. 123, pp. e18–e209, 2011.
- S. C. Smith Jr., E. J. Benjamin, R. O. Bonow, et al., “AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation,” Circulation, vol. 124, pp. 2458–2473, 2011.
- Heart Protection Study Collaborative Group, “MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002.
- C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004.
- J. C. LaRosa, S. M. Grundy, D. D. Waters et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435, 2005.
- T. R. Pedersen, O. Faergeman, J. J. P. Kastelein et al., “High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial,” Journal of the American Medical Association, vol. 294, no. 19, pp. 2437–2445, 2005.
- Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, “Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: a double-blind randomized trial,” The Lancet, vol. 376, pp. 1658–1669, 2010.
- Cholesterol Treatment Trialists’ (CTT) Collaboration, “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials,” The Lancet, vol. 376, pp. 1670–1681, 2010.
- J. Hsia, J. G. MacFadyen, J. Monyak, and P. M. Ridker, “Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin: the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin),” Journal of the American College of Cardiology, vol. 57, no. 16, pp. 1666–1675, 2011.
- S. M. Grundy, J. I. Cleeman, N. B. Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004.
- L. Mosca, E. J. Benjamin, K. Berra, et al., “Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American heart association,” Circulation, vol. 123, pp. 1243–1262.
- J. D. Brunzell, M. Davidson, C. D. Furberg et al., “Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation,” Diabetes Care, vol. 31, no. 4, pp. 811–822, 2008.
- A. L. Catapano, J. Chapman, O. Wiklund, and M. R. Taskinen, “The new joint EAS/ESC guidelines for the management of dyslipidaemias,” Atherosclerosis, vol. 217, no. 1, p. 1, 2011.
- D. G. Karalis, R. D. Subramanya, S. E. Hessen, L. Liu, and M. F. Victor, “Achieving optimal lipid goals in patients with coronary artery disease,” American Journal of Cardiology, vol. 107, no. 6, pp. 886–890, 2011.
- H. Ghandehari, S. Kamal-Bahl, and N. D. Wong, “Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004,” American Heart Journal, vol. 156, no. 1, pp. 112–119, 2008.
- M. H. Davidson, K. C. Maki, T. A. Pearson et al., “Results of the National Cholesterol Education (NCEP) program evaluation project utilizing novel T-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations,” American Journal of Cardiology, vol. 96, no. 4, pp. 556–563, 2005.
- D. D. Waters, C. Brotons, C. W. Chiang et al., “Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals,” Circulation, vol. 120, no. 1, pp. 28–34, 2009.
- L. T. Meade, “Barriers to achieving LDL cholesterol goals,” U.S. Pharmacist, vol. 32, no. 3, pp. 66–71, 2007.
- A. B. Kauffman, K. L. Olson, M. L. Youngblood, E. B. Zadvorny, T. Delate, and J. A. Merenich, “Attainment of low-density lipoprotein cholesterol goals in coronary artery disease,” Journal of Clinical Lipidology, vol. 4, no. 3, pp. 173–180, 2010.
- L. Mosca, N. B. Merz, R. S. Blumenthal et al., “Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting,” Circulation, vol. 111, no. 4, pp. 488–493, 2005.
- A. G. Kennedy, C. D. MacLean, B. Littenberg, P. A. Ades, and R. G. Pinckney, “The challenge of achieving national cholesterol in patients with diabetes,” Diabetes Care, vol. 28, no. 5, pp. 1029–1034, 2005.
- T. A. Stacy and A. Egger, “Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs,” Journal of Managed Care Pharmacy, vol. 12, no. 9, pp. 745–751, 2006.
- A. T. Yan, R. T. Yan, M. Tan et al., “Contemporary management of dyslipidemia in high-risk patients: targets still not met,” American Journal of Medicine, vol. 119, no. 8, pp. 676–683, 2006.
- L. Laforest, P. Moulin, T. Souchet et al., “Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy,” Atherosclerosis, vol. 199, no. 2, pp. 368–377, 2008.
- E. Stein, S. Stender, P. Mata et al., “Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin,” American Heart Journal, vol. 148, no. 3, pp. 447–455, 2004.
- M. H. Davidson, T. McGarry, R. Bettis et al., “Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia,” Journal of the American College of Cardiology, vol. 40, no. 12, pp. 2125–2134, 2002.
- H. S. Friedman, S. Rajagopalan, J. P. Barnes, and H. Roseman, “Combination therapy with Ezetimibe/Simvastatin versus Statin Monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting,” Clinical Therapeutics, vol. 33, no. 2, pp. 212–224, 2011.
- The SHARP Investigators, “The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of Heart and Renal Protection): a randomized placebo-controlled trial,” The Lancet, vol. 377, pp. 2181–2192, 2011.
- A. J. Taylor, T. C. Villines, E. J. Stanek et al., “Extended-release niacin or ezetimibe and carotid intima-media thickness,” The New England Journal of Medicine, vol. 361, no. 22, pp. 2113–2122, 2009.
- C. M. Ballantyne, M. H. Davidson, J. McKenney, L. H. Keller, D. R. Bajorunas, and R. H. Karas, “Comparison of the safety and efficacy of a combination tablet of niacin extended release and Simvastatin versus Simvastatin monotherapy in patients with increased Non-HDL cholesterol (from the SEACOAST I study),” American Journal of Cardiology, vol. 101, no. 10, pp. 1428–1436, 2008.
- The AIM-HIGH Investigators, “Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy,” The New England Journal of Medicine, vol. 365, pp. 2255–2267, 2011.
- G. A. Nichols and C. E. Koro, “Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients,” Clinical Therapeutics, vol. 29, no. 8, pp. 1761–1770, 2007.
- J. M. Foody, S. G. Sajjan, X. H. Hu et al., “Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients,” Journal of Clinical Lipidology, vol. 4, no. 2, pp. 126–132, 2010.
- The ACCORD Study Group, “Effects of combination lipid therapy in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 362, pp. 1563–1574, 2010.
- B. V. Howard, M. J. Roman, R. B. Devereux et al., “Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial,” Journal of the American Medical Association, vol. 299, no. 14, pp. 1678–1689, 2008.